Abstract
Goals of therapy for inflammatory bowel disease have advanced beyond symptom control to the normalization of biomarkers of inflammation, and mucosal healing in particular, with the expectation that this will change the natural history of these diseases. Concurrent with higher treatment expectations has come an expanded therapeutic armamentarium to achieve these goals, and a greater ability to optimize each therapeutic class to maximize therapeutic benefits and minimize unnecessary treatment failures. In addition to these advances has come the evolution of therapeutic drug monitoring which is increasingly being utilized to optimize the use of immunomodulators and biologic therapies in particular. This review will outline the principals of optimization of the conventional medical therapies available to the clinician today.
Keywords: Aminosalicylates, allopurinol, anti-tumor necrosis factor agents, corticosteroids, thiopurines, thioguanine nucleotides, therapeutic drug monitoring.
Current Drug Targets
Title:Optimizing Conventional Medical Therapies in Inflammatory Bowel Disease in 2014
Volume: 15 Issue: 11
Author(s): Anil Kumar Asthana, Miles P. Sparrow and Laurent Peyrin-Biroulet
Affiliation:
Keywords: Aminosalicylates, allopurinol, anti-tumor necrosis factor agents, corticosteroids, thiopurines, thioguanine nucleotides, therapeutic drug monitoring.
Abstract: Goals of therapy for inflammatory bowel disease have advanced beyond symptom control to the normalization of biomarkers of inflammation, and mucosal healing in particular, with the expectation that this will change the natural history of these diseases. Concurrent with higher treatment expectations has come an expanded therapeutic armamentarium to achieve these goals, and a greater ability to optimize each therapeutic class to maximize therapeutic benefits and minimize unnecessary treatment failures. In addition to these advances has come the evolution of therapeutic drug monitoring which is increasingly being utilized to optimize the use of immunomodulators and biologic therapies in particular. This review will outline the principals of optimization of the conventional medical therapies available to the clinician today.
Export Options
About this article
Cite this article as:
Asthana Kumar Anil, Sparrow P. Miles and Peyrin-Biroulet Laurent, Optimizing Conventional Medical Therapies in Inflammatory Bowel Disease in 2014, Current Drug Targets 2014; 15 (11) . https://dx.doi.org/10.2174/1389450115666140915113503
DOI https://dx.doi.org/10.2174/1389450115666140915113503 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Efforts to Develop Imaging Methods and β -Cell-Specific Contrast Agents for Non-Invasive in vivo Assessment of β-Cell Mass
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Whole Embryo Culture: An Important Tool in Developmental Toxicology Today
Current Pharmaceutical Design Influence of Polymorphic N-Acetyltransferases on Non-Malignant Spontaneous Disorders and on Response to Drugs
Current Drug Metabolism Optimization of Cardiac Metabolism in Diabetes Mellitus
Current Pharmaceutical Design Gallic Acid Attenuates Oleic Acid-induced Proliferation of Vascular Smooth Muscle Cell Through Regulation of AMPK-eNOS-FAS Signaling
Current Medicinal Chemistry Renal Innervation in Resistant Hypertension: A Review of Pathophysiology and Renal Denervation as Potential Treatment
Current Hypertension Reviews Towards High Resolution Optical Imaging of Beta Cells In Vivo
Current Pharmaceutical Design Animal Models of Lupus and Lupus Nephritis
Current Pharmaceutical Design Association of Thrombospondin-1 (N700S) and Thrombospond in-4 (A387P) Gene Polymorphisms with the Incidence of Acute Myocardial Infarction in Egyptians
Current Pharmaceutical Biotechnology EDITORIAL [Hot Topic: Diabetes Cardiovascular Complications (Guest Editor: Costanza Emanueli)]
Endocrine, Metabolic & Immune Disorders - Drug Targets A Critical Evaluation of Adenosine A2A Receptors as Potentially “Druggable” Targets in Huntingtons Disease
Current Pharmaceutical Design Enzymes Inhibition and Antidiabetic Effect of Isolated Constituents from Callistemon lanceoalatus
The Natural Products Journal Diet and Nutritional Interventions with the Special Role of Myo-Inositol in Gestational Diabetes Mellitus Management. An Evidence-Based Critical Appraisal
Current Pharmaceutical Design Challenges for Gene Therapy of Type 1 Diabetes
Current Gene Therapy Cell Adhesion Molecules and Cadmium
Current Chemical Biology NKT Cell Subsets Can Exert Opposing Effects in Autoimmunity, Tumor Surveillance and Inflammation
Current Immunology Reviews (Discontinued) The Role of Endothelial Progenitor Cells and Statins in Endothelial Function: A Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Antimicrobial Agents-Associated with QT Interval Prolongation
Current Drug Safety Effects of Senna didymobotrya Root Extract and Compounds on Tritoninduced Hyperlipidaemic Rats and Differentiation of 3T3-Li Preadipocytes
The Natural Products Journal Management of Type 2 Diabetes: More Evidence is Required to Address the Clinical and Contextual Facets
Current Diabetes Reviews